04:22 PM EDT, 06/21/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Friday it has seen "positive" new results from a phase 1/2 trial of VX-880 to treat people with type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemic events.

Updated results on 12 people who were given the full dose of VX-880 as a single infusion are "consistent with previously reported positive results in the VX-880 trial and reinforce the transformative potential of this therapy," the company said.

Vertex also said that all three people who had at least one year of follow-up reached the primary endpoint of elimination of severe hypoglycemic events and the secondary endpoint of insulin independence.

The company also said it has obtained regulatory approval to expand study enrollment.